Table 1 Clinical characteristics of cohort
From: Genomic alterations related to HPV infection status in a cohort of Chinese prostate cancer patients
Characteristics | Mean age, yr, \(\pm\) SD | Age group, yr, no. (%) | Total, no | |
|---|---|---|---|---|
< 70 | ≥ 70 | |||
|  | 72.83 ± 6.22 | 15 (25.4) | 44 (74.6) | 59 |
tPSA (ng/ml) | Â | Â | Â | Â |
 < 4 | 73 ± 2.71 | 0 (0.0) | 4 (100.0) | 4 |
 4–10 | 73.33 ± 6.92 | 3 (25.0) | 9 (75.0) | 12 |
 > 10 | 72.65 ± 6.44 | 11 (31.4) | 24 (68.6) | 35 |
 NA | / | 1 (12.5) | 7 (87.5) | 8 |
|  | P = 0.953 | P = 0.610 |  | |
fPSA/tPSA | Â | Â | Â | Â |
 < 0.16 | 71.92 ± 6.05 | 13 (36.1) | 23 (63.9) | 36 |
 ≥ 0.16 | 75.71 ± 6.12 | 0 (0.0) | 14 (100.0) | 14 |
 NA | / | 1 (11.1) | 8 (88.9) | 9 |
|  | P = 0.060 | P = 0.010 |  | |
ISUP group | Â | Â | Â | Â |
 1 | 74.64 ± 8.52 | 2 (18.2) | 9 (81.8) | 11 |
 2 | 72.64 ± 6.34 | 5 (35.7) | 9 (64.3) | 14 |
 3 | 73.15 ± 3.67 | 2 (15.4) | 11 (84.6) | 13 |
 4 | 70.7 ± 6.88 | 4 (40.0) | 6 (60.0) | 10 |
 5 | 72.82 ± 5.67 | 2 (18.2) | 9 (81.8) | 11 |
|  | P = 0.721 | P = 0.571 |  | |
T stage | Â | Â | Â | Â |
 1 | 75.6 ± 11.19 | 2 (40.0) | 3 (60.0) | 5 |
 2 | 73.32 ± 5.37 | 6 (21.4) | 22 (78.6) | 28 |
 3 | 70.38 ± 5.25 | 4 (25.0) | 12 (75.0) | 16 |
 4 | 74 ± 6.62 | 3 (30.0) | 7 (70.0) | 10 |
|  | P = 0.265 | P = 0.809 |  | |
N stage | Â | Â | Â | Â |
 0 | 72.65 ± 6.15 | 13 (25.5) | 38 (74.5) | 51 |
 1 | 74.80 ± 7.69 | 1 (20.0) | 4 (80.0) | 5 |
 X | 72.67 ± 6.81 | 1 (33.3) | 2 (66.7) | 3 |
|  | P = 0.767 | P = 1.000 |  | |
M stage | Â | Â | Â | Â |
 0 | 72.76 ± 6.247 | 15 (25.9) | 43 (74.1) | 58 |
 1 | 77 ± 0.0 | 0 (0.0) | 1 (100.0) | 1 |
|  | P = 0.504 | P = 1.000 |  | |